This excerpt taken from the ABT 8-K filed Oct 15, 2008.
XIENCE V U.S. Launch Exceeding Expectations
This excerpt taken from the ABT 8-K filed Apr 16, 2008.
XienceTM V Abbott also presented data on its Xience V drug-eluting stent. Results from the SPIRIT II clinical trial outside the United States demonstrated that after two years, patients with the Xience V stent experienced a 40 percent reduction in major adverse cardiac events (MACE) compared to Boston Scientifics Taxus drug-eluting stent. Two-year results from Abbotts U.S. pivotal trial, SPIRIT III, have been accepted as a LateBreaker presentation at the upcoming EuroPCR meeting in mid-May.